All Stories

  1. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies
  2. Characteristics and mechanisms of cognitive impairment in Parkinson disease
  3. An Alternative Approach to the Finger‐Tapping Test in Parkinsonian Patients: Finger to Crease Instead of Finger to Tip
  4. Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease
  5. Progressive Supranuclear Palsy—A Global Review
  6. Early Subtypes and Progressions of Progressive Supranuclear Palsy: A Data-Driven Brain Bank Study
  7. Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein
  8. T cell responses towards PINK1 and α-synuclein are elevated in prodromal Parkinson’s disease
  9. Association of CSF α-Synuclein Seeding Amplification Assay Results With Clinical Features of Possible and Probable Dementia With Lewy Bodies
  10. Why Crafting a Compelling Abstract Is Important to Summarize Research Findings
  11. Biosensor Strip for Rapid On‐site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease
  12. Biosensor Strip for Rapid On‐site Assessment of Levodopa Pharmacokinetics along with Motor Performance in Parkinson's Disease
  13. PINK1 is a target of T cell responses in Parkinson’s disease
  14. Nicked tRNAs are stable reservoirs of tRNA halves in cells and biofluids
  15. CBD diagnostic criteria: exclusions as important as inclusions
  16. Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies
  17. Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
  18. Nicked tRNAs are stable reservoirs of tRNA halves in cells and biofluids
  19. Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology
  20. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments
  21. Physician‐Assisted Dying: Access and Utilization in Patients with Movement Disorders
  22. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
  23. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
  24. Orthostatic hypotension preceding dementia with Lewy bodies by over 15 years: a clinicopathologic case report
  25. Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?
  26. Hypertension and progressive supranuclear palsy
  27. Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability
  28. End of life planning in parkinsonian diseases
  29. The virtual reality of Parkinson's disease freezing of gait: A systematic review
  30. Progress in the treatment of Parkinson-Plus syndromes
  31. Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions
  32. Therapeutic options for Progressive Supranuclear Palsy including investigational drugs
  33. The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy
  34. Which ante mortem clinical features predict progressive supranuclear palsy pathology?
  35. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
  36. Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease
  37. Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study
  38. Understanding falls in progressive supranuclear palsy
  39. Progression of brain atrophy in PSP and CBS over 6 months and 1 year
  40. Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale
  41. Abolishing the 1-year rule: How much evidence will be enough?
  42. Environmental Exposures and Parkinson’s Disease
  43. Cognitive functioning in individuals with Parkinson’s disease and traumatic brain injury: A longitudinal study
  44. Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
  45. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials
  46. Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study
  47. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease
  48. α-synuclein genetic variability: A biomarker for dementia in Parkinson disease
  49. The new definition and diagnostic criteria of Parkinson's disease
  50. Technology in Parkinson's disease: Challenges and opportunities
  51. Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
  52. Relationship between uric acid levels and progressive supranuclear palsy
  53. Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study
  54. Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy
  55. Progressive supranuclear palsy: progression and survival
  56. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy
  57. Structural MRI Correlates of Episodic Memory Processes in Parkinson’s Disease Without Mild Cognitive Impairment
  58. Swallowing disturbances in the corticobasal syndrome
  59. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis
  60. Head injury exposure in PSP: a case-control study
  61. MDS clinical diagnostic criteria for Parkinson's disease
  62. MDS research criteria for prodromal Parkinson's disease
  63. The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease
  64. Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers)
  65. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy
  66. Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report
  67. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
  68. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases
  69. Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy
  70. The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World
  71. Correcting for Demographic Variables on the Modified Telephone Interview for Cognitive Status
  72. A disposable electrochemical biosensor for l-DOPA determination in undiluted human serum
  73. Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
  74. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
  75. Faculty Opinions recommendation of Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.
  76. P3‐165: MILD COGNITIVE IMPAIRMENT AMONG PARKINSON'S DISEASE SUBJECTS IN THE UNIFORM DATA SET
  77. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
  78. Corticobasal Degeneration
  79. The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment
  80. Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status
  81. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
  82. Cognition in movement disorders: Where can we hope to be in ten years?
  83. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease
  84. Instrumental activities of daily living are impaired in Parkinson’s disease patients with mild cognitive impairment.
  85. Rate of decline in progressive supranuclear palsy
  86. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
  87. Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinson’s Disease
  88. Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy
  89. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria
  90. Behavioral abnormalities in progressive supranuclear palsy
  91. Faculty Opinions recommendation of Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
  92. Primary Health Care Providers' Knowledge Gaps on Parkinson's Disease
  93. Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson’s disease
  94. Parkinsonian Syndromes
  95. Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease
  96. Neuropsychiatric and cognitive disorders in other parkinsonian disorders
  97. Faculty Opinions recommendation of The natural history of multiple system atrophy: a prospective European cohort study.
  98. P4–096: APOE‐ɛ4 and clinical progression in Parkinson's disease
  99. The meaning of a “hippo” response on the Montreal Cognitive Assessment in Parkinson's disease
  100. Measuring mild cognitive impairment in patients with Parkinson's disease
  101. Criteria for the diagnosis of corticobasal degeneration
  102. Functional impairment in progressive supranuclear palsy
  103. White-Matter Changes Correlate with Cognitive Functioning in Parkinson’s Disease
  104. Long-duration Parkinson's disease: Role of lateralization of motor features
  105. Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease
  106. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease
  107. Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy
  108. Faculty Opinions recommendation of Pareidolias: complex visual illusions in dementia with Lewy bodies.
  109. Faculty Opinions recommendation of Parkinson subtypes progress differently in clinical course and imaging pattern.
  110. Executive Dysfunction Is the Primary Cognitive Impairment in Progressive Supranuclear Palsy
  111. Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines
  112. The pill questionnaire in a nondemented Parkinson's disease population
  113. Faculty Opinions recommendation of Clinical features of Parkinson disease when onset of diabetes came first: A case-control study.
  114. Pan-American Consortium of Multiple System Atrophy. Preliminary Report (P06.079)
  115. Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study
  116. Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2
  117. Phosphorylated  -Synuclein in Parkinson's Disease
  118. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
  119. Annonacin in Asimina triloba fruit: Implication for neurotoxicity
  120. Roles of Education and IQ in Cognitive Reserve in Parkinson’s Disease-Mild Cognitive Impairment
  121. Faculty Opinions recommendation of Quantitative EEG as a predictive biomarker for Parkinson disease dementia.
  122. Cytokine expression and microglial activation in progressive supranuclear palsy
  123. Faculty Opinions recommendation of α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.
  124. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome
  125. Parkinsonism and Frontotemporal Dementia: The Clinical Overlap
  126. Progressive Supranuclear Palsy and Corticobasal Degeneration
  127. Brain-Lung-Thyroid Disease
  128. Copy Number Variation in Familial Parkinson Disease
  129. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
  130. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
  131. Faculty Opinions recommendation of Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.
  132. Milestones in atypical and secondary Parkinsonisms
  133. Assessment of cognition in early dementia
  134. Woman with gait impairment and difficulty reading
  135. Faculty Opinions recommendation of Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
  136. A recommended scale for cognitive screening in clinical trials of Parkinson's disease
  137. Cognitive and neuropsychiatric effects of subthalamotomy for Parkinson’s disease
  138. Faculty Opinions recommendation of Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.
  139. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
  140. Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease
  141. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
  142. Faculty Opinions recommendation of Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
  143. H1/H1 genotype influences symptom severity in corticobasal syndrome
  144. Faculty Opinions recommendation of Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.
  145. Bradykinesia
  146. Tauopathies
  147. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
  148. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria
  149. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort
  150. Genomewide association study for onset age in Parkinson disease
  151. Faculty Opinions recommendation of Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.
  152. Faculty Opinions recommendation of Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study.
  153. Faculty Opinions recommendation of A controlled trial of antidepressants in patients with Parkinson disease and depression.
  154. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
  155. Review article Progressive supranuclear palsy revisited
  156. Reply: Corticobasal syndrome with Alzheimer's disease pathology
  157. Parkinson’s Disease: An Overview of Pathogenesis
  158. Is it PD, PSP, CBD, DLB, or MSA?
  159. Faculty Opinions recommendation of Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
  160. Genomewide association study for susceptibility genes contributing to familial Parkinson disease
  161. The Gly2019Ser mutation in LRRK2is not fully penetrant in familial Parkinson's disease: the GenePD study
  162. Faculty Opinions recommendation of Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.
  163. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study
  164. Replication of association between ELAVL4 and Parkinson disease: the GenePD study
  165. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study
  166. Faculty Opinions recommendation of Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia.
  167. Progressive supranuclear palsy and corticobasal degeneration: similarities and differences
  168. Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)
  169. Preface
  170. Current and future therapeutic approaches in progressive supranuclear palsy
  171. Biology and Neuropathology of Dementia in Syphilis and Lyme Disease
  172. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
  173. Clinical and Therapeutic Aspects of Dementia in Syphilis and Lyme Disease
  174. Clinical aspects and biology of normal pressure hydrocephalus
  175. Clinical aspects of Parkinson dementia
  176. Clinical symptoms in Alzheimer's disease
  177. History of Dementia
  178. Mild cognitive impairment
  179. Neuropathology and genetics of corticobasal degeneration
  180. Neuropathology of Pick body disease
  181. Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism
  182. Perspectives of Alzheimer's disease treatments
  183. Quality of Life in Dementias
  184. The Epidemiology of vascular dementia
  185. The Neuropathology of Vascular and Mixed Dementia and Vascular Cognitive Impairment
  186. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
  187. Update of atypical parkinsonian disorders
  188. Clinical diagnostic criteria for dementia associated with Parkinson's disease
  189. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II
  190. The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I
  191. Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms
  192. Faculty Opinions recommendation of Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial.
  193. Faculty Opinions recommendation of Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
  194. Neurobiology of Progressive Supranuclear Palsy
  195. Unraveling progressive supranuclear palsy: from the bedsideback to the bench
  196. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study
  197. Alzheimer's disease presenting as corticobasal syndrome
  198. Measuring quality of life in PSP
  199. Faculty Opinions recommendation of Compulsive drug use linked to sensitized ventral striatal dopamine transmission.
  200. Atypical Parkinsonian Disorders--Clinical and Research Aspects * Edited by Irene Litvan * Human Press, 2005. ISBN 1-588-29-331-9. $175.00
  201. Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease
  202. Current and future treatments in progressive supranuclear palsy
  203. Penguins and hummingbirds: Midbrain atrophy in progressive supranuclear palsy
  204. Faculty Opinions recommendation of Substantia nigra tangles are related to gait impairment in older persons.
  205. Faculty Opinions recommendation of A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
  206. Book Review Drug Induced Movement Disorders Second edition. Edited by Stewart A. Factor, Anthony E. Lang, and William J. Weiner. 466 pp. Malden, Mass., Blackwell Futura, 2005. $120. 1-4051-2619-1
  207. Lrrk2 and Lewy body disease
  208. Midbrain atrophy in progressive supranuclear palsy: comparison of two dimensional planimetric- with three dimensional volumetric measurements
  209. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study
  210. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
  211. High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy
  212. Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski’s description of PSP 40 years ago and Albert’s delineation of the subcortical dementia 30 years ago
  213. “Applause sign” helps to discriminate PSP from FTD and PD
  214. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome
  215. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response
  216. Atypical Parkinsonian Disorders
  217. What is an Atypical Parkinsonian Disorder?
  218. Progressive Supranuclear Palsy
  219. Progressive Supranuclear Palsy and Corticobasal Degeneration
  220. Update on progressive supranuclear palsy
  221. ATYPICAL PARKINSONIAN DISORDERS
  222. Diagnostic issues in non-AD dementias
  223. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration
  224. Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees
  225. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?
  226. Update on epidemiological aspects of progressive supranuclear palsy
  227. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease
  228. SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
  229. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy
  230. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia
  231. Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?
  232. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
  233. Freezing of gait in postmortem‐confirmed atypical parkinsonism
  234. Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy
  235. Corticobasal Degeneration and Related Disorders
  236. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease
  237. Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders
  238. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
  239. Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype
  240. Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy
  241. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype
  242. Therapy and management of frontal lobe dementia patients
  243. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy
  244. An open letter to the Committee on The Nobel Prize in Medicine
  245. Impairment of eyeblink classical conditioning in progressive supranuclear palsy
  246. Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders
  247. Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease
  248. Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease
  249. Diagnosis and Management of Progressive Supranuclear Palsy
  250. The FAB
  251. Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study
  252. Research goals in progressive supranuclear palsy
  253. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease
  254. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy
  255. Language disturbances in corticobasal degeneration
  256. Pupillary diameter assessment: Need for a graded scale
  257. Frontal Assessment Battery
  258. Importance of deficits in executive functions
  259. Evaluation of surgery for Parkinson’s disease
  260. Progression of falls in postmortem-confirmed Parkinsonian disorders
  261. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study
  262. Atypical parkinsonism in the French West Indies
  263. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias
  264. Recent advances in atypical parkinsonian disorders
  265. Effects of Physostigmine on Swallowing and Oral Motor Functions in Patients with Progressive Supranuclear Palsy: A Pilot Study
  266. Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy
  267. Clinicopathologic Case Report
  268. Consensus statement on the diagnosis of multiple system atrophy
  269. Ideomotor apraxia in progressive supranuclear palsy: A case study
  270. Ideomotor apraxia in progressive supranuclear palsy: A case study
  271. A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration
  272. Consensus statement on the diagnosis of multiple system atrophy
  273. Parkinsonian Features
  274. Caregiving in progressive supranuclear palsy
  275. Neuropsychiatric features of corticobasal degeneration
  276. Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders
  277. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study
  278. Reliability of the NINDS Myotatic Reflex Scale
  279. Pharmacological Therapy in Progressive Supranuclear Palsy
  280. Is EEG useful in the differential diagnosis of parkinsonism?
  281. Apathy Is Not Depression
  282. Dysfunction of Ib (Autogenic) spinal inhibition in patients with progressive supranuclear palsy
  283. Clinical and Genetic Aspects of Progressive Supranuclear Palsy
  284. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies
  285. Progressive supranuclear palsy
  286. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy
  287. Apolipoprotein Eepsilon4 (Epsilon) Allele Does Not Affect the Onset or Symptom Severity in Progressive Supranuclear Palsy
  288. What are the Obstacles for an Accurate Clinical Diagnosis of Pick's disease?
  289. Methodological and Research Issues in the Evaluation of Biological Diagnostic Markers for Alzheimer’s Disease
  290. Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI). 22The ...
  291. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination
  292. PROGRESSIVE SUPRANUCLEAR PALSY
  293. Limb shaking in multiple system atrophy
  294. Progressive supranuclear gaze palsy is in linkage disequilibrium with theτ and not the α-synuclein gene
  295. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration
  296. What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?
  297. The clinical and pathologic hallmarks of progressive supranuclear palsy
  298. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism
  299. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study
  300. Characterizing swallowing abnormalities in progressive supranuclear palsy
  301. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study
  302. Accuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study
  303. REPLY FROM THE AUTHORS
  304. A Reappraisal of Reliability and Validity Studies in Stroke
  305. Neuropsychiatric aspects of progressive supranuclear palsy
  306. Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?
  307. Reliability of the NINDS Myotatic Reflex Scale
  308. Preserved cognitive processes in cerebellar degeneration
  309. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop
  310. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.
  311. Visualizing Cortical Activation during Mental Calculation with Functional MRI
  312. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
  313. Progressive supranuclear palsy: a clinicopathological study of 21 cases
  314. 641 Accuracy of the clinical diagnosis of pick's disease
  315. Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders
  316. What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?
  317. Neuropsychological Features of Progressive Supranuclear Palsy
  318. What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?
  319. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
  320. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy
  321. Cognitive disturbances in progressive supranuclear palsy
  322. Cholinergic approaches to the treatment of progressive supranuclear palsy
  323. Cerebellar cognition
  324. Cognitive planning deficit in patients with cerebellar atrophy
  325. CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy
  326. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
  327. Progressive supranuclear palsy
  328. Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.
  329. Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy
  330. Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function
  331. Selective deficits in cognition and memory in high-functioning parkinsonian patients.
  332. Frontal Lobe Function in Progressive Supranuclear Palsy
  333. Implicit Learning in Patients with Alzheimer's Disease
  334. Physostigmine treatment of progressive supranuclear palsy
  335. Memory Impairment in Patients With Progressive Supranuclear Palsy
  336. Multiple Memory Deficits in Patients With Multiple Sclerosis
  337. Slowed Information Processing in Multiple Sclerosis
  338. Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease
  339. Behcet's syndrome masquerading as tumor
  340. Does reversed laterality really exist in dextrals? A case study
  341. Agitation and Apathy in Hyper- and Hypokinetic Movement Disorders
  342. Measuring quality of life in progressive supranuclear palsy
  343. Management of cognitive impairment in Parkinson's disease
  344. Faculty of 1000 evaluation for Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.
  345. Case Studies